Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Chinese PLA General Hospital
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07374198CT.gov Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression | — | Not Yet Recruiting | — | — | — |
NCT07374211CT.gov Effect of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Severe Depression | — | Not Yet Recruiting | — | — | — |
NCT07367542CT.gov Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery | — | Not Yet Recruiting | — | — | — |
NCT07146503CT.gov Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anxiety Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jnj-54135419 (this asset) | Chinese PLA General Hospital | N/A | D · 30 |
| Risperidone | Tianjin Medical University General Hospital | P4 | BBB |
| Sertraline | Holland Bloorview Kids Rehabilitation Hospital | P4 | BBB |
| Olanzapine | Tianjin Medical University General Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Theresa Jacob, PhD, MPH | P4 | BBB |
| Fluoxetine | Hannover Medical School | P4 | BBB |
| Escitalopram | Wake Forest University Health Sciences | P4 | BB |
| Vortioxetine | H. Lundbeck A/S | P4 | BB |
| Dinitrogen Monoxide | Beth Israel Deaconess Medical Center | P4 | BB |
+42 more in the Anxiety Disorder cohort
Other indications for Jnj-54135419
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Depressive Disorder | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 73 |
| Major Depressive Disorder | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jnj-54135419 in Anxiety Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jnj-54135419-anxiety-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →